跳到主要内容
Moderna is up 666% this year YTD.
The biggest catalyst was its successful Phase 3 melanoma trial.
The major catalysts through Oct. 15:
• January: stronger finances and durable cancer data.
Better-than-expected preliminary 2025 sales and cost reductions eased cash-burn